Barchart on MSN
Moderna jumps above 20-day moving average on FDA flu vaccine review. Should you buy MRNA stock here?
Moderna (MRNA) stock closed higher on Wednesday after the FDA reversed its earlier refusal-to-file decision on the company’s ...
Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent ...
Scripps News on MSN
FDA reverses course, will review Moderna’s mRNA flu vaccine candidate
After an initial rejection, the FDA will review Moderna’s mRNA flu vaccine for adults 50+, aiming for approval by the 2026-27 ...
CAMBRIDGE, MA / ACCESS Newswire / July 28, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that three abstracts on its investigational mRNA therapeutics have been accepted for presentation at the ...
Moderna Inc (NASDAQ:MRNA) has delivered a 37% gain year-to-date, dramatically outpacing the biotech sector’s 0.4% YTD return. In fact, Moderna has the 12th-best gains in the entire S&P 500 so far in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results